Why Tenax Therapeutics, Inc.’s (TENX) Stock Is Down 5.73%
As of Wednesday, July 29, Tenax Therapeutics, Inc.’s TENX share price has dipped by 5.73%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Commentary & Analysis
Why Tenax Therapeutics, Inc.’s (TENX) Stock Is Up 5.37%
As of Monday, July 27, Tenax Therapeutics, Inc.’s TENX share price has surged by 5.37%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tenax Therapeutics, Inc.’s (TENX) Stock Is Down 6.04%
As of Wednesday, July 22, Tenax Therapeutics, Inc.’s TENX share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tenax Therapeutics, Inc.’s (TENX) Stock Is Up 5.21%
As of Friday, July 17, Tenax Therapeutics, Inc.’s TENX share price has surged by 5.21%, which has investors questioning if this is right time to sell.Michael Rose
Why Tenax Therapeutics, Inc.’s (TENX) Stock Is Down 6.32%
As of Monday, July 13, Tenax Therapeutics, Inc.’s TENX share price has dipped by 6.32%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | TENX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $700.0 | $252.6 | 41% |
|
| Shares Out (Mil) | 45.2 | 52.3 | 45% |
|
| Institutional Ownership | 99.8% | 92.1% | 94% |
|
| Float (Mil) | 26.5 | 40.2 | 34% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 1,496 | 455 | 77% |
|
| Price Change (52-week) |
119.9% | 52.9% | 94% |
|
| Growth | TENX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (39.7%) | (9.9%) | 9% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | na | 8 | |
| Current EPS | ($0.361) | na | ($1.441) | |
| Month Ago EPS | ($0.362) | na | ($1.439) | |
| # Rev Up | 0 | na | 0 | |
| # Rev Down | 1 | na | 1 | |
| Three Months Ago EPS | ($0.410) | na | ($1.557) | |
| Year/Year Chg | 4.0% | na | na | |
| Financials | TENX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($58) | ($43) | 15% |
|
| EPS (TTM) | ($1.399) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $542 | $180 | 35% |
|
| Valuation | TENX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.83 | 2.56 | 82% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TENX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (49.2%) | (49.8%) | 12% |
|
| ROE | (51.7%) | (55.5%) | 15% |
|
| Liabilities to Assets | 6.9% | 30.3% | 3% |
|
| F-Score | 1 | 3 | 1% |
|
Tenax Therapeutics, Inc. did not pass any screens on 7/31/2026.
